Myelodysplastic Syndromes
Improving the efficiency of drug approvals in MDS
In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel…
Date: 14th September 2022
The need for more effective first-line therapies in MDS
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early…
Date: 7th September 2022
Clonal hematopoiesis and pre-MDS states
The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in…
Date: 24th August 2022
High-risk MDS: unmet needs and future treatment approaches
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a…
Date: 19th August 2022
CAR-T therapy in AML: challenges and future outlooks
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…
Date: 10th August 2022
Updates in classification and risk stratification in MDS
Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years,…
Date: 27th July 2022
Immune dysregulation and targeting in MDS
Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in…
Date: 22nd July 2022
The impact of AI and machine learning algorithms in MDS
Artificial intelligence (AI) and machine learning algorithms are transforming treatment and prognosis in hematological malignancies, as well as other areas…
Date: 13th May 2022
ASH 2021: what did ASH 2021 mean for MDS?
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments…
Date: 18th March 2022
EHA 2021: updates on treatment for MDS
Myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their…
Date: 26th July 2021
The MDS Sessions: highlights from ASCO/EHA 2021
Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not…
Date: 8th July 2021
MDS Session: Women in Science
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 17th May 2021
